Euroscreen S.A.

Euroscreen is developing lead compounds across a number of therapeutic areas, with our own programs targeting applications for unmet medical needs.

Euroscreen will develop its drug candidate portfolio to maximize value and profit from partnerships at the preclinical and clinical stages. ESN 364 is on-track to enter clinical development in 2013.